PROVe study: Treatment of MF-CTCL Patients #EORTC2019

PROVe study: Treatment of MF-CTCL Patients #EORTC2019

User Photo

11 months
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0

Ellen J. Kim, MD of @PennMedicine explains the PROVe Study on efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies. #EORTC19


Dr. Ellen J. Kim, UPENN, Professor of Dermatology, Penn Cutaneous Lymphoma Program, PROVe principal investigator, said: “The rarity of MF-CTCL has resulted in there being limited knowledge available for those affected by this disease, as well as many clinicians. We are pleased to have conducted the PROVe study and to further highlight our findings at the EORTC, as we set out to further expand our knowledge concerning the field of MF and current treatment options. The observational study assessed nearly 300 patients and verified that continued treatment of MF-CTCL patients with chlormethine gel is important and associated with improved patients' health-related quality of life.”

Up Next Autoplay